Kimberly-Clark Corporation

Kimberly-Clark raised its quarterly dividend from $1.26 to $1.28 per share in January 2026, bringing the annual payout to $5.12 per share and a yield of about 4.6% with the stock near $110. The company has increased its dividend for 54 consecutive years and paid dividends for 92 years, supported by essential brands like Huggies, Kleenex, and Scott that hold No. 1 or No. 2 positions in roughly 70 countries. Cash from operations including discontinued operations reached $1.7 billion in the first half of 2026, up from $1.1 billion a year earlier, while capital spending rose to $776 million from $401 million and dividends paid totaled $843 million. Management expects about $2 billion in adjusted free cash flow for 2026, roughly in line with 2025, despite plans to spend about $1.3 billion on capital investments. The pending Kenvue acquisition, expected to close in the fourth quarter of 2026, is projected to add about $1.9 billion in cost synergies and another $500 million in profit from revenue synergies within three to four years of closing, though integration risks remain.

Kimberly-Clark has launched a proprietary program using hesperaloe, an arid climate plant, to develop next-generation materials for hygiene products. The initiative aims to support sustainability goals and supply chain resilience as consumer and regulatory attention on ESG continues to rise. The company, with a market cap of $36.8b, relies on large volumes of fiber-based materials for its personal care portfolio. The program is positioned to support a premium, science-led hygiene strategy and could differentiate products from competitors like Procter & Gamble and Colgate-Palmolive. Analysts have flagged debt levels and dividend coverage as pressure points, and a large-scale ramp-up of a new materials supply chain could tighten financial flexibility if returns take time to show.

Kenvue narrowly missed Wall Street estimates for second-quarter results as inflation, tariffs, and currency-related costs squeezed margins. Adjusted gross margin fell to 60.2% from 60.9% a year earlier, while adjusted profit came in at 31 cents per share, just below the 32-cent analyst estimate. Quarterly sales rose 3% to $3.96 billion, slightly missing the $3.97 billion consensus. The consumer-health company, currently in the midst of a $40 billion buyout by Kimberly-Clark, expects the deal to close in the fourth quarter of 2026.

Several companies announced dividend declarations. Kimberly-Clark declared a regular quarterly dividend of $1.28 per share, payable on October 2, 2026 to stockholders of record on September 4, 2026. Westlake Chemical Partners declared a distribution of $0.4714 per unit, its 48th quarterly distribution since its initial public offering, payable on August 28, 2026 to unit holders of record on August 13, 2026. Eagle Materials declared a quarterly cash dividend of $0.25 per share, payable on October 13, 2026 to stockholders of record on September 14, 2026. Robert Half declared a quarterly cash dividend of $0.59 per share, payable on September 15, 2026 to shareholders of record on August 25, 2026. Western Union declared a quarterly cash dividend of $0.235 per common share, payable on September 30, 2026 to stockholders of record on September 16, 2026. Northern Oil and Gas declared a cash dividend of $0.45 per share, equal to the prior quarterly dividend, payable on October 30, 2026 to stockholders of record on September 29, 2026.

Kenvue Inc. remains a closely watched consumer health name as investors weigh trusted brands, improving margins and a major pending transaction. In the first quarter of 2026, adjusted gross margin expanded 80 basis points to 60.8% and adjusted operating margin improved 420 basis points to 24%, driven by supply-chain productivity and cost optimization actions. Skin Health and Beauty net sales increased 8.4%, with organic sales up 5%, supported by volume growth and innovation such as Neutrogena's entry into sun care in select EMEA markets. The pending cash-and-stock combination with Kimberly-Clark Corporation, under which Kenvue shareholders are expected to receive 0.14625 Kimberly-Clark shares plus $3.50 in cash per Kenvue share, has received shareholder approvals and U.S. antitrust clearance, with closing expected in the second half of 2026. The stock currently carries a Zacks Rank #3 (Hold), with Value, Growth and VGM Scores of C and a Momentum Score of D, reflecting a balanced near-term view.

The global adult diapers market is projected to grow from USD 14.16 billion in 2025 to USD 32.19 billion by 2035, at a compound annual growth rate of 8.22 percent, according to a new report by SNS Insider. North America held a 33 percent revenue share in 2025, with the U.S. market alone valued at USD 4.39 billion and expected to reach USD 8.79 billion by 2035. Europe was valued at USD 4.09 billion in 2025 and is forecast to hit USD 8.82 billion by 2035, while Asia-Pacific is set to be the fastest-growing region with a CAGR of 10.52 percent. Pull-up pants led product types with a 39 percent market share, retail pharmacies dominated distribution with 34 percent, urinary incontinence accounted for 56 percent of applications, and homecare settings captured 48 percent of end-user demand. Key players include Essity, Kimberly-Clark, Unicharm, and Ontex, with recent innovations focusing on improved absorbency, skin protection, and sustainable materials.

Jim Cramer highlighted Kimberly-Clark as a defensive holding on CNBC's Mad Money, citing its acquisition of Kenvue, Johnson & Johnson's former consumer health business. The deal adds brands like Tylenol, Neutrogena, Listerine, and Band-Aids, creating a high-margin powerhouse with steady cash flow through economic cycles. Kimberly-Clark trades at roughly 14 times earnings, near its lowest multiple in a decade, and offers a 4.74% dividend yield after raising its quarterly payout to $1.28 per share, backed by 54 consecutive years of dividend increases. Cramer sees the stock as a long-term opportunity with potential upside from the Kenvue integration, though he does not expect a blowout second-quarter report on August 4th. Institutional investors own about 93% of the company, while a 14.5% short float could fuel a squeeze if integration results beat expectations.

Kimberly-Clark, a Dividend King with 54 consecutive years of dividend increases, offers a 4.7% yield and is positioned for solid returns following a strategic shift. The company recently formed a joint venture called Arbex with pulp supplier Suzano, offloading its lower-margin paper-towel and tissue business to focus on higher-margin personal-care products while retaining licensing royalties. This move frees up resources to integrate its pending acquisition of Kenvue, a consumer health company spun off from Johnson & Johnson in 2023, which Kimberly-Clark expects will generate approximately $1.9 billion in cost synergies and roughly $500 million in profit from revenue synergies within three to four years of closing. Analysts have a median price target of $113 per share, implying 5% upside, and the stock trades at 14 times earnings.

Arbex, the joint venture formed by Kimberly-Clark Corp and Suzano, started operating as an independent company on July 1. The $3.4 billion joint venture is positioned to pursue opportunities as an international tissue and hygiene company with operations in more than 70 markets, producing and selling leading global and regional brands including Kleenex, Scott, Cottonelle, Andrex, and Viva. It has assumed ownership of assets previously run by Kimberly-Clark's International Family Care & Professional business unit, which includes 22 manufacturing sites in 14 countries. Earlier on June 17, Piper Sandler reiterated a Buy rating on Kimberly-Clark Corp and raised the price target to $121 from $115, citing an incrementally favorable cost outlook and strong productivity momentum.

Kimberly-Clark reported that its innovation-led strategy delivered a 3% improvement in volume plus mix growth in the first quarter of fiscal 2026, marking two consecutive years of broad-based gains. The company emphasized that these improvements were driven primarily by product innovation rather than promotional activity, with promotional programs designed only to support product launches and accelerate adoption. In the quarter, promotions centered on the enhanced Snug & Dry offering, which features a softer feel from a redesigned absorbent core, contributing to higher household penetration and improved product velocities. Kimberly-Clark is building market share across its key focus areas of Baby Care, Women's Health, and Active Aging by consistently introducing differentiated products that address evolving consumer needs. The company's continued investment in consumer-centric innovation is reinforcing its competitive position and supporting sustainable, profitable organic growth over the long term.

Four Dividend Kings are significantly outperforming the S&P 500's 9% gain in 2026 while offering reliable dividends backed by over 50 consecutive years of increases. Target surged 32% year to date and still trades at a cheap valuation with a 3.56% dividend yield. Colgate-Palmolive extended its 63-year dividend growth streak with a roughly 20.4% gain. Coca-Cola rose more than 16%, extending its 64-year dividend streak, and Kimberly-Clark advanced over 13% while yielding 4.41% and pursuing a $48.7 billion acquisition of Kenvue. All four stocks are rated Buy by top Wall Street firms.

Kimberly-Clark has risen 13.7% year to date, outpacing the S&P 500 and Nasdaq Composite, and offers a 4.5% dividend yield. The company’s recession-resistant portfolio of household brands like Huggies and Kleenex supports consistent demand, while management expects to recover input cost inflation and expand margins over time. A pending acquisition of consumer health company Kenvue, approved by shareholders, is set to close before year-end and is projected to deliver $2.1 billion in annual run rate synergies by the second year. Kimberly-Clark trades at 15.2 times consensus 2026 earnings estimates, well below its 10-year median price-to-earnings ratio of 21.9, and has raised its dividend for 54 consecutive years.

Kimberly-Clark has announced a planned $48.7 billion acquisition of Kenvue, a deal that would integrate Kenvue into Kimberly-Clark's consumer products portfolio. Kenvue, which trades on the NYSE under the ticker KVUE, last closed at $19.33, with the stock up 2.8% over the past week and 11.4% over the past month. Over the past year the share price declined 3.2% and over three years it declined 15.0%. Investors are watching for updates on how the deal could affect Kenvue's operations, capital allocation, and brand priorities, as well as any guidance on margins, capital spending, and future capital returns.

Piper Sandler raised its price target on Kimberly-Clark Corporation to $121 from $115 while maintaining an Overweight rating. The firm cited manageable cost headwinds supported by solid productivity gains and a recent drop in oil prices. The new target reflects a multiple of approximately 16 times 2027 expected earnings per share, up from 15 times. Piper Sandler also noted expanded June merchandising and expects innovation to pick up in the latter half of 2026. The firm anticipates $150 million to $170 million in additional gross inflation assuming oil at $100 per barrel, compared with $80 currently, and said upside from the KVUE transaction will not be realized until 2028.

Kimberly-Clark’s dividend payout ratio has climbed near 80%, but the balance sheet tells a more reassuring story for income investors. The company paid $1.28 per share on July 2, 2026, extending its annual increase streak to 53 years, though free cash flow barely covered the dividend in fiscal 2025 at 0.99 times. However, shareholder equity jumped 79% to $1.502 billion in 2025 while total debt fell by $620 million, slashing the debt-to-equity ratio from 9.42 times to 4.86 times. In the first quarter of 2026, operating cash flow surged 128% year over year to $745 million, and adjusted earnings per share of $1.97 beat estimates. The pending $48.7 billion acquisition of Kenvue and a mid-2026 joint venture with Suzano are set to reshape the asset base, with management guiding for double-digit adjusted EPS growth.

A bullish thesis on Kimberly-Clark Corporation highlights the company's transformation into a higher-margin enterprise, supported by a 5.19% dividend yield and 54 consecutive years of dividend increases. Fourth-quarter 2025 results showed net income rising to $499 million and adjusted EPS growing 24% to $1.86, despite a slight sales decline. For the full year, sales reached $16.4 billion with 1.7% organic growth and adjusted EPS of $7.53. Management expects double-digit constant-currency adjusted EPS growth and approximately $2 billion in adjusted free cash flow, though risks include an elevated 83.07% payout ratio and category maturity.

Five Dividend Kings—companies with 50 or more consecutive years of dividend increases—offer retirees dependable income and stability as markets rotate away from volatile tech names. Altria yields 5.9% after its 57th consecutive dividend hike, while Kimberly-Clark pays nearly 5% after its shares fell 23% in 2025. Hormel Foods offers a 4.77% yield and is restructuring to cut costs, Sonoco Products pays 4.20% and makes constantly in-demand packaging, and Genuine Parts has raised its dividend for 69 consecutive years, trades at just 12 times forward earnings, and holds a Raymond James Strong Buy rating.

Kimberly-Clark Corporation highlighted nine consecutive quarters of volume and share growth at the 23rd annual dbAccess Global Consumer Conference on June 4, 2026. The company credited its Powering Care strategy for the momentum, noting that Huggies has been elevated to an 80 percent premium tier in the U.S. while value offerings are expanding globally. It is tracking ahead on its 3 billion dollar productivity program, having already delivered 56 percent of the target. International markets performed strongly, led by double-digit growth in Brazil, Indonesia, Vietnam, and Korea. The company also announced that Pull-Ups launched Learning Layer technology in Canada on June 8, 2026, a potty-training innovation that briefly delays fluid absorption to help toddlers learn wetness cues.

The Motley Fool identifies Church & Dwight, Keurig Dr Pepper, and Kenvue as consumer staples companies offering predictable demand for a $1,000 investment during uncertain markets. Church & Dwight beat first-quarter 2026 guidance with 5% organic sales growth driven entirely by volume, and it acquired Miss Mouth's Messy Eater for $325 million in May. Keurig Dr Pepper's stock is down nearly 29% from its 2025 peak despite beating revenue estimates for four straight quarters, while its energy drink portfolio including Ghost, C4, Venom, and Black Rifle Energy is expected to generate well over $1 billion in annual retail sales. Kenvue's skin health and beauty division grew 8.4% in the first quarter of 2026, and its pending merger with Kimberly-Clark is expected to close in the second half of the year, creating one of the largest consumer health and personal care platforms globally.

Piper Sandler raised its price target on Kimberly-Clark to $121 from $115 while reiterating an Overweight rating. The firm noted that potential benefits from the Kenvue deal are unlikely to appear in results until 2028 but could be meaningful over time. For now, Piper Sandler models only the legacy business because pro-forma segment details have not been provided. During the first-quarter 2026 earnings call, Chairman and CEO Michael Hsu said the company continued to gain market share in Baby Care, Women's Health, and Active Aging, and that the second-quarter product launch schedule would be one of the busiest in its history. CFO Nelson Urdaneta said a fire at the California distribution center is expected to reduce second-quarter revenue by about $20 million, with second-quarter earnings facing an estimated $50 million impact from Middle East conflict-related inflation and fire costs. Looking to the second half, Urdaneta stated that if oil prices average around $100 per barrel, Kimberly-Clark could see additional gross input cost pressures of roughly $150 million to $170 million.

Kenvue, the consumer health spinoff from Johnson & Johnson, is trading around $18.32 per share, well below the $21.01 per share total consideration offered in its pending $40 billion mega-merger with Kimberly-Clark. The deal, already approved by shareholders of both companies but still subject to foreign regulatory approvals, would give Kenvue investors $3.50 in cash plus 0.14625 Kimberly-Clark shares for each Kenvue share held. The combined company expects to capture roughly $2.1 billion in run rate cost synergies by giving local markets full profit-and-loss ownership while leveraging Kimberly-Clark’s global supply chain. Kenvue, a Dividend King with 63 consecutive years of payout increases, currently yields 4.53% and owns iconic brands such as Tylenol, Listerine, Neutrogena, and Band-Aid, while its first-quarter revenue rose 4.5% year over year to $3.9 billion and earnings per share jumped 47% to $0.25.